Abstract
An 80-year-old patient with castrate-resistant prostate cancer presented to our department for PSMA imaging because of a rising prostate-specific antigen (PSA) level. The tumor was diagnosed in 2004. GnRh analog was the only treatment the patient received. Two cycles of Lu-PSMA-617 were performed with a 2-month interval in between. Ten months after finishing with 2 cycles of Lu-PSMA therapy, we noticed a continuous falling PSA level and a decreasing tumor spread in the PET/CT imaging just under the hormone therapy.
MeSH terms
-
Aged, 80 and over
-
Dipeptides / therapeutic use*
-
Heterocyclic Compounds, 1-Ring / therapeutic use*
-
Humans
-
Lutetium / therapeutic use*
-
Male
-
Neoplasm Metastasis
-
Positron Emission Tomography Computed Tomography
-
Prostate-Specific Antigen
-
Prostatic Neoplasms, Castration-Resistant / diagnostic imaging
-
Prostatic Neoplasms, Castration-Resistant / pathology*
-
Prostatic Neoplasms, Castration-Resistant / radiotherapy*
-
Radioisotopes*
-
Treatment Outcome
Substances
-
Dipeptides
-
Heterocyclic Compounds, 1-Ring
-
PSMA-617
-
Radioisotopes
-
Lutetium
-
Prostate-Specific Antigen